| Summary: | Background: Subclinical hypothyroidism (SCH) as a compensated or preclinical type of primary and overt hypothyroidism (OHT) can affect approximately 4–10% of the general population. Treating SCH can slowdown the progression to OHT, the formation of cardiovascular diseases, neuropsychiatric symptoms, and other miscellaneous problems. Materials and Methods: The present study is a case-control study that was conducted on 239 adults who were referred to 501 Imam Reza Hospital from March 2019 up to September 2019. Of the 239 patients and their families admitted to the hospital, 121 (50.6%) were euthyroid (as control group) and the remaining participants (118, 49.4%) were SCH (as case group). The serum levels of thyroid stimulating hormone (TSH), urea, uric acid, creatinine, T3, and T4 were asked to be determined at a single laboratory. Biochemical markers of kidney function and the level of thyroid hormones were compared between the two groups of euthyroid and SCH. Results: TSH was significantly higher in SCH (7.25 (4.4-18.15)) compared to euthyroid (1.4 (0.2-3.7)) patients (P < 0.001). Among biochemical markers, creatinine (P < 0.001) and uric acid (P = 0.006) had higher serum levels in the case group. There was no remarkable difference in the thyroxine hormone levels and urea between the euthyroid and SCH patients (P > 0.05). Within the SCH group, there was a significant positive correlation between TSH and the level of creatinine (P = 0.001, r = 0.302). Conclusion: Regular monitoring of the major function of the kidneys in patients with hypothyroidism and SCH can help early diagnosis of kidney dysfunction, thus increasing the chance of restoring normal kidney function.
|
|---|
